Official blog
Compliance-aware guides and brand updates for adult consumers.
Page 31 of 35 / 832 articles
For decades, the industry's most effective defense has been a single argument: smokers choose to smoke. The appeal to personal responsibility has been devastatingly effective at blocking regulation—and it's back.
The nicotine patch was a pharmaceutical breakthrough: a steady, continuous dose of nicotine without the peaks and troughs of smoking. Four decades later, it remains the most widely used cessation aid—and its limitations are instructive.
Smokers feel judged, stigmatized, and excluded by the very public health campaigns designed to help them quit. The result is a trust deficit that undermines cessation. Can tobacco control rebuild the relationship?
People living with HIV smoke at two to three times the general population rate, and smoking now kills more HIV-positive people than the virus itself. For this population, harm reduction isn't theoretical—it's urgent.
When Philip Morris funds a study showing vaping helps smokers quit, is it science or marketing? When the WHO funds a study showing vaping is dangerous, is it objectivity or institutional bias? The funding question is inescapable.
Progressives have led the fight against smoking for decades. But the rise of harm reduction has split the coalition—pitting public health pragmatists against precautionary-principle advocates in a battle over values.
In 2019, a mysterious lung illness killed 68 people and hospitalized nearly 3,000. EVALI triggered a panic about vaping. The cause was eventually identified. The lessons have been selectively remembered.
Nicotine use is surprisingly common among elite athletes—not for recreation, but for performance. The phenomenon challenges the simplistic narrative of nicotine as purely a harmful addiction.
Every smoker knows smoking causes cancer. But ask them about their personal risk, and the answer changes. The gap between general knowledge and personal belief is one of psychology's most lethal phenomena.
From the UK to France to Australia, nations are racing to ban disposable e-cigarettes. But banning a product doesn't make it disappear—it changes who sells it, who buys it, and what's in it.
Vape advocates love comparing nicotine to caffeine. Tobacco controllers call it dangerous misinformation. Both have a point. Here's what the analogy gets right, what it gets wrong, and why it matters.
What actually happens inside the body—hour by hour, day by day, year by year—after a smoker quits? The repair process is one of the most remarkable in human biology, and understanding it can be the difference between relapse and recovery.
When the U.S. banned shipping vaping products through the mail in 2021, it was framed as a youth protection measure. Two years later, the results are mixed—and the law of unintended consequences is working overtime.
Early in the pandemic, a paradoxical finding emerged: smokers seemed underrepresented in COVID-19 hospitalizations. The ensuing scientific scramble revealed both the dangers of premature conclusions and the complexity of nicotine's biology.
A growing number of governments are taxing e-cigarettes at rates comparable to combustible cigarettes. The logic is revenue and parity. The effect is to make the safer product less affordable relative to the deadly one.
The world's largest tobacco company and the world's top health authority are locked in a propaganda war over the future of nicotine. Both claim to follow the science. Both accuse the other of distortion. Who actually controls the narrative?
People with mental health conditions smoke at twice the rate of the general population and die 10–20 years earlier, largely from smoking-related diseases. Addressing this gap is the most urgent—and most neglected—priority in tobacco control.
Menthol and mint are the most popular e-liquid flavors among both adults and teens. Ban them, and you risk driving adult vapers back to smoking. Keep them, and you preserve the youth-appealing flavor that's hardest to justify.
TikTok, Instagram, and YouTube didn't create youth vaping—but they've made it visible, viral, and normalized in ways that regulators are only beginning to understand. The algorithm is the new advertising.
NRT—patches, gum, lozenges—is safe, effective, and available over the counter. So why do fewer than 10% of quit attempts involve it? The answer reveals uncomfortable truths about access, education, and addiction stigma.
Cannabis vape cartridges now dominate legal marijuana markets—and the playbook looks familiar. From flavor names to Instagram marketing, the cannabis industry is replicating nicotine vaping's trajectory, including its mistakes.
As Western smoking rates plummet, the tobacco industry is betting its future on Africa—a continent with young populations, weak regulation, and rising incomes. The battle for Africa's lungs is just beginning.
Twin studies, genome-wide association scans, and neuroimaging genetics are revealing that smoking behavior is substantially heritable. Understanding the genetic architecture of nicotine addiction could transform cessation—and raise ethical questions.
Flavors help adult smokers quit. Flavors attract teenagers to start. Both statements are true and supported by evidence. The policy challenge is that they describe the same products, and we can't ban one without affecting the other.
Products
Select a product to view details, highlights, and technical specifications.
